ReviewDiabetology & metabolic syndrome2026
Association of glucagon-like peptide-1 receptor agonist therapy with atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis.
Review in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide, with a rising global prevalence. Post-ablation AF recurrence remains frequent, particularly among patients with obesity and metabolic syndrome. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated favorable cardiometabolic and cardiovascular effects, but their association with AF recurrence after ablation remains uncertain.
methodsPubMed, Scopus, Embase, and Web of Science were searched through June 18, 2026. Cohort studies evaluating GLP-1RA therapy in adults with atrial fibrillation undergoing catheter ablation were included. The primary outcome was post-ablation atrial fibrillation recurrence (or recurrent atrial tachyarrhythmia, as defined by the individual studies). Adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using a random-effects model. Risk of bias was assessed using the JBI tool, and certainty of evidence was evaluated using the GRADE approach.
resultsSix cohort studies (three prospective and three retrospective), comprising 14,278 patients (7,065 GLP-1RA users and 7,213 controls), met the inclusion criteria. Follow-up duration ranged from 12 to 24 months across studies. The pooled mean age was approximately 64 years in both the GLP-1RA and control groups. GLP-1RA therapy was associated with a lower hazard of AF recurrence compared with the respective comparator groups (HR = 0.74, 95% CI 0.63-0.87; I² = 50.5%). However, the certainty of the evidence was low because the findings were derived predominantly from observational studies.
conclusionsObservational evidence suggests that GLP-1RA use is associated with a lower hazard of AF recurrence following catheter ablation. However, these findings should be interpreted cautiously, and further high-quality randomized controlled trials are required to confirm this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.